Repurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Synucleinophaties are progressive neurodegenerative disorders with no cure to date. An attractive strategy to tackle this problem is repurposing already tested safe drugs against novel targets. In this way, doxycycline prevents neurodegeneration in Parkinson models by modulating neuroinflammation. However, anti-inflammatory therapy per se is insufficient to account for neuroprotection. Herein we characterise novel targets of doxycycline describing the structural background supporting its effectiveness as a neuroprotector at subantibiotic doses. Our results show that doxycycline reshapes α-synuclein oligomers into off-pathway, high-molecular-weight species that do not evolve into fibrils. Off-pathway species present less hydrophobic surface than on-pathway oligomers and display different β-sheet structural arrangement. These structural changes affect the α-synuclein ability to destabilize biological membranes, cell viability, and formation of additional toxic species. Altogether, these mechanisms could act synergically giving novel targets for repurposing this drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, recent studies demonstrated that DOX reduces the size and load of α-synuclein oligomers by converting them into high-molecular weight species that are not able to form fibrils, thus increasing cell viability [282,284].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [284]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Molecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Svergun, D. I. (1992) · Journal of Applied Crystallography · doi:10.1107/s0021889892001663 · Cited by 3,759
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 2,868
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., & Stefani, M. (2002) · Nature · doi:10.1038/416507a · Cited by 2,434
[18] Quantification of β-sheet amyloid fibril structures with thioflavin T
LeVine, H. (1999) · Methods in Enzymology · doi:10.1016/s0076-6879(99)09020-5 · Cited by 1,365
Amyloid pores from pathogenic mutations
Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., & Lansbury, P. T. (2002) · Nature · doi:10.1038/418291a · Cited by 1,289
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Luk, K. C., Song, C., O'Brien, P., Stieber, A., Branch, J. R., Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908005106 · Cited by 938
Arrondo, J. L. R., Muga, A., Castresana, J., & Goñi, F. M. (1993) · Progress in Biophysics and Molecular Biology · doi:10.1016/0079-6107(93)90006-6 · Cited by 865
Dependence of α-Synuclein Aggregate Morphology on Solution Conditions
Hoyer, W., Antony, T., Cherny, D., Heim, G., Jovin, T. M., & Subramaniam, V. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00775-1 · Cited by 565
Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease
Zhang, Y., Dawson, V. L., & Dawson, T. M. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0319 · Cited by 407
ANS Binding Reveals Common Features of Cytotoxic Amyloid Species
Bolognesi, B., Kumita, J. R., Barros, T. P., Esbjorner, E. K., Luheshi, L. M., Crowther, D. C., Wilson, M. R., Dobson, C. M., Favrin, G., & Yerbury, J. J. (2010) · ACS Chemical Biology · doi:10.1021/cb1001203 · Cited by 389
Clinical, Cosmetic and Investigational Dermatology
(2020) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid · Cited by 353
Burgos‐Morón, E., Calderón‐Montaño, J. M., Salvador, J., Robles, A., & López‐Lázaro, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.24967 · Cited by 336
Curcumin Modulates α-Synuclein Aggregation and Toxicity
Singh, P. K., Kotia, V., Ghosh, D., Mohite, G. M., Kumar, A., & Maji, S. K. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn3001203 · Cited by 307
Neuropathology of synuclein aggregates: New insights into mechanisms of neurodegenerative diseases
Duda, J. E., Lee, V. M.-Y., & Trojanowski, J. Q. (2000) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20000715)61:2<121::aid-jnr1>3.0.co;2-4 · Cited by 264
Toxic prefibrillar α-synuclein amyloid oligomers adopt a distinctive antiparallel β-sheet structure
Celej, M. S., Sarroukh, R., Goormaghtigh, E., Fidelio, G. D., Ruysschaert, J.-M., & Raussens, V. (2012) · Biochemical Journal · doi:10.1042/bj20111924 · Cited by 245
Spreading of Neurodegenerative Pathology via Neuron-to-Neuron Transmission of -Amyloid
Nath, S., Agholme, L., Kurudenkandy, F. R., Granseth, B., Marcusson, J., & Hallbeck, M. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0615-12.2012 · Cited by 244
Low‐dose doxycycline therapy: Effect on gingival and crevicular fluid collagenase activity in humans
Golub, L. M., Ciancio, S., Ramamurthy, N. S., Leung, M., & McNamara, T. F. (1990) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.1990.tb00923.x · Cited by 227
Tong, J., Wong, H., Guttman, M., Ang, L. C., Forno, L. S., Shimadzu, M., Rajput, A. H., Muenter, M. D., Kish, S. J., Hornykiewicz, O., et al. (2010) · Brain · doi:10.1093/brain/awp282 · Cited by 206
Neuroprotection by tetracyclines
Domercq, M., & Matute, C. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.10.001 · Cited by 205
How Epigallocatechin Gallate Can Inhibit α-Synuclein Oligomer Toxicity in Vitro
Lorenzen, N., Nielsen, S. B., Yoshimura, Y., Vad, B. S., Andersen, C. B., Betzer, C., Kaspersen, J. D., Christiansen, G., Pedersen, J. S., Jensen, P. H., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.554667 · Cited by 202
Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease
Gustot, A., Gallea, J. I., Sarroukh, R., Celej, M. S., Ruysschaert, J.-M., & Raussens, V. (2015) · Biochemical Journal · doi:10.1042/bj20150617 · Cited by 184
Structural Characteristics of α-Synuclein Oligomers Stabilized by the Flavonoid Baicalein
Hong, D.-P., Fink, A. L., & Uversky, V. N. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.08.039 · Cited by 177
Finer, E. G., Flook, A. G., & Hauser, H. (1972) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(72)90073-2 · Cited by 175
Minocycline reduces gadolinium‐enhancing magnetic resonance imaging lesions in multiple sclerosis
Metz, L. M., Zhang, Y., Yeung, M., Patry, D. G., Bell, R. B., Stoian, C. A., Yong, V. W., Patten, S. B., Duquette, P., Antel, J. P., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20111 · Cited by 171
Doxycycline Suppresses Microglial Activation by Inhibiting the P38 MAPK and NF-KB Signaling Pathways
Santa-Cecília, F. V., Socias, B., Ouidja, M. O., Sepulveda-Diaz, J. E., Acuña, L., Silva, R. L., Michel, P. P., Del-Bel, E., Cunha, T. M., & Raisman-Vozari, R. (2016) · Neurotoxicity Research · doi:10.1007/s12640-015-9592-2 · Cited by 165
Self-citationKaylor, J., Bodner, N., Edridge, S., Yamin, G., Hong, D.-P., & Fink, A. L. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.08.046 · Cited by 159
α-Synuclein and Mitochondria: Partners in Crime?
Nakamura, K. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0182-9 · Cited by 149
Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis
Gordon, P. H., Moore, D. H., Gelinas, D. F., Qualls, C., Meister, M. E., Werner, J., Mendoza, M., Mass, J., Kushner, G., & Miller, R. G. (2004) · Neurology · doi:10.1212/01.wnl.0000125321.92112.7e · Cited by 139
Anti‐Inflammatory Properties of Low and High Doxycycline Doses: An In Vitro Study
Di Caprio, R., Lembo, S., Di Costanzo, L., Balato, A., & Monfrecola, G. (2015) · Mediators of Inflammation · doi:10.1155/2015/329418 · Cited by 136
Yim, C. W., Flynn, N. M., & Fitzgerald, F. T. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.28.2.347 · Cited by 133
Binolfi, A., Rodriguez, E. E., Valensin, D., D’Amelio, N., Ippoliti, E., Obal, G., Duran, R., Magistrato, A., Pritsch, O., Zweckstetter, M., et al. (2010) · Inorganic Chemistry · doi:10.1021/ic1016752 · Cited by 130
Self-citationDoxycycline restrains glia and confers neuroprotection in a 6‐OHDA Parkinson model
Lazzarini, M., Martin, S., Mitkovski, M., Vozari, R. R., Stühmer, W., & Bel, E. D. (2013) · Glia · doi:10.1002/glia.22496 · Cited by 117
Self-citationExploring the Association Between Rosacea and Parkinson Disease: A Danish Nationwide Cohort Study
Egeberg, A., Hansen, P. R., Gislason, G. H., & Thyssen, J. P. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0022 · Cited by 116
Ligand-Target Interactions: What Can We Learn from NMR?
Carlomagno, T. (2005) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.34.040204.144419 · Cited by 115
Ardah, M. T., Paleologou, K. E., Lv, G., Abul Khair, S. B., Kazim, A. S., Minhas, S. T., Al-Tel, T. H., Al-Hayani, A. A., Haque, M. E., Eliezer, D., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00197 · Cited by 114
Minocycline in Huntington's disease: A pilot study
Thomas, M., Ashizawa, T., & Jankovic, J. (2004) · Movement Disorders · doi:10.1002/mds.20018 · Cited by 111
Giorgetti, S., Raimondi, S., Pagano, K., Relini, A., Bucciantini, M., Corazza, A., Fogolari, F., Codutti, L., Salmona, M., Mangione, P., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178376 · Cited by 104
Lendel, C., Bertoncini, C. W., Cremades, N., Waudby, C. A., Vendruscolo, M., Dobson, C. M., Schenk, D., Christodoulou, J., & Tóth, G. (2009) · Biochemistry · doi:10.1021/bi901285x · Cited by 103
Plotegher, N., Gratton, E., & Bubacco, L. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.02.013 · Cited by 95
Safety and efficacy of doxycycline in the treatment of rosacea
Sánchez, J. L., Valentín‐Nogueras, S. M., Morales, A., & Rivera, A. (2009) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s4296 · Cited by 89
Cho, Y., Son, H. J., Kim, E.-M., Choi, J. H., Kim, S. T., Ji, I. J., Choi, D. H., Joh, T. H., Kim, Y. S., & Hwang, O. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9078-1 · Cited by 85
Costa, R., Speretta, E., Crowther, D. C., & Cardoso, I. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274548 · Cited by 80
Effect of curcumin analogs onα-synuclein aggregation and cytotoxicity
Jha, N. N., Ghosh, D., Das, S., Arunagiri, A., Jacob, R. S., Singh, P. K., Ayyagari, N., Namboothiri, I. N. N., & Maji, S. K. (2016) · Scientific Reports · doi:10.1038/srep28511 · Cited by 77
Ceftriaxone Blocks the Polymerization of α-Synuclein and Exerts Neuroprotective Effects in Vitro
Ruzza, P., Siligardi, G., Hussain, R., Marchiani, A., Islami, M., Bubacco, L., Delogu, G., Fabbri, D., Dettori, M. A., Sechi, M., et al. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn400149k · Cited by 70
Heemskerk, J. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02236-1 · Cited by 69
Tetracyclines and Prion Infectivity
Forloni, G., Salmona, M., Marcon, G., & Tagliavini, F. (2009) · Infectious Disorders - Drug Targets · doi:10.2174/1871526510909010023 · Cited by 62
THE EFFECT OF pH AND SALT CONCENTRATION ON AQUEOUS EXTRACTION OF BRAIN PROTEINS AND LIPOPROTEINS*
LeBaron, F. N., & Folch, J. (1959) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1959.tb13168.x · Cited by 60
Non-Steroidal Anti-Inflammatory Drug Use and the Risk of Parkinson’s Disease
Manthripragada, A. D., Schernhammer, E. S., Qiu, J., Friis, S., Wermuth, L., Olsen, J. H., & Ritz, B. (2011) · Neuroepidemiology · doi:10.1159/000325653 · Cited by 57
Pukaß, K., & Richter‐Landsberg, C. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-013-0154-x · Cited by 52
Phthalocyanines as Molecular Scaffolds to Block Disease-Associated Protein Aggregation
Valiente‐Gabioud, A. A., Miotto, M., Chesta, M. E., Lombardo, V. A., Binolfi, A., & Fernández, C. O. (2016) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00507 · Cited by 51
Self-citationAntioxidant effect of doxycycline decreases MMP activity and blood pressure in SHR
Antonio, R. C., Ceron, C. S., Rizzi, É., Coelho, E. B., Tanus-Santos, J. E., & Gerlach, R. F. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1848-7 · Cited by 46
Reduction of central nervous system reperfusion injury in rabbits using doxycycline treatment.
Clark, W. M., Calcagno, F. A., Gabler, W. L., Smith, J. R., & Coull, B. M. (1994) · Stroke · doi:10.1161/01.str.25.7.1411 · Cited by 44
Chen, Y., Wu, C., Shieh, J., Wu, J., Chen, H., Chung, T.-W., Chen, Y.-K., & Lin, C. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/124747 · Cited by 40
Ávila, C., Torres-Bugeau, C. M., Barbosa, L. R. S., Sales, E. M., Ouidja, M., Socias, S., Celej, M. S., Raisman-Vozari, R., Papy-Garcia, D., Itri, R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.544288 · Cited by 31
Self-citation
Cited by
Old Drugs as New Treatments for Neurodegenerative Diseases
Durães, F., Pinto, M., & Sousa, E. (2018) · Pharmaceuticals · doi:10.3390/ph11020044 · Cited by 343
“Furthermore, doxycycline (10) has only been reported to bind to oligomeric species of α-synuclein; the physiological monomeric forms are preserved [77].”
BackgroundGut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment
Salim, S., Ahmad, F. A., Banu, A., & Mohammad, F. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.10.013 · Cited by 133
Alpha Synuclein: Neurodegeneration and Inflammation
Forloni, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065914 · Cited by 122
Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease
Bortolanza, M., Nascimento, G. C., Socías, S. B., Ploper, D., Chehín, R. N., Raisman‐Vozari, R., & Bel, E. A. D. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1913-1 · Cited by 109
Self-citationVaresi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
Metadata
- Authors
- González-Lizárraga, F., Socías, S. B., Ávila, C. L., Torres-Bugeau, C. M., Barbosa, L. R. S., Binolfi, A., Sepúlveda-Díaz, J. E., Del-Bel, E., Fernandez, C. O., Papy-Garcia, D., Itri, R., Raisman-Vozari, R., & Chehín, R. N.
- Affiliations
- National University of Tucumán (AR)
- Universidade de São Paulo (BR)
- Corresponding author
- Chehín, Rosana N.
- Venue
- Scientific Reports
- Published
- 2017-02-03
- Volume
- 7
- Issue
- 1
- Pages
- 41755-41755
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5290535
- OpenAlex
- W2584036292
- Cited by
- 119
- References
- 61
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 6 · 2023: 13 · 2022: 18 · 2021: 21 · 2020: 23 · 2019: 13 · 2018: 8 · 2017: 4
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Americanae (AECID Library) (publishedVersion, other-oa)
- HAL (submittedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Greater South Information System
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2014/)
- Consejo Nacional de Investigaciones Científicas y Técnicas (PIP-CONICET 0183)
- Ministerio de Ciencia, Tecnología e Innovación Productiva
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Campus France
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- doxycycline, drug repurposing, synucleinopathies, alpha-synuclein oligomers, Parkinson's disease, neuroprotection, membrane perturbation, neuroinflammation, hydrophobic surfaces, neurodegeneration
- MeSH terms
- Protein Conformation, beta-Strand, Cell Survival, Doxycycline, Humans, Models, Molecular, Magnetic Resonance Spectroscopy, Protein Binding, Spectroscopy, Fourier Transform Infrared, Neurodegenerative Diseases, Cell Line, Tumor, alpha-Synuclein, Protein Multimerization, Drug Repositioning, Protein Aggregation, Pathological, Protein Aggregates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.